Press-release for stocks for ALNY

symbols : ALNY

save search

Alnylam Reports Positive Topline Results from APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Published: 2022-08-03 (Crawled : 12:00) - biospace.com/
SNYNF | News | $94.25 -2.18% 480

Health Technology

| -6.49% | O: -2.6% H: 0.0% C: -0.76%
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -5.05% | O: -0.17% H: 0.12% C: -1.29%
ALNY | $143.8 -1.55% -1.58% 390K

Health Technology

| 2.89% | O: 47.44% H: 0.0% C: 0.0%
topline positive results study

New Long-Term Results for GIVLAARI® (givosiran) Presented at ASH Annual Meeting & Exposition
Published: 2021-12-13 (Crawled : 00:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K

Health Technology

| -16.86% | O: 6.02% H: 2.03% C: -0.29%
givlaari results

New Results from Phase 1 Study of Cemdisiran + Pozelimab Presented at ASH Annual Meeting 2021
Published: 2021-12-14 (Crawled : 03:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K

Health Technology

| -16.86% | O: 6.02% H: 2.03% C: -0.29%
phase 1 results phase 2 phase 3

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress™ 2022
Published: 2022-06-08 (Crawled : 12:00) - globenewswire.com
VIR | $8.04 -1.11% -1.12% 770K

Health Technology

| -67.45% | O: 5.76% H: 0.45% C: -5.37%
ALNY | $143.8 -1.55% -1.58% 390K

Health Technology

| 11.7% | O: 4.17% H: 0.0% C: 0.0%
hepatitis liver presentation international

Alnylam Reports Updated Positive Interim Phase 1 Results for ALN-APP, in Development for Alzheimer’s Disease and Cerebral Amyloid Angiopathy
Published: 2023-07-17 (Crawled : 09:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| -10.72% | O: 0.02% H: 0.0% C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K

Health Technology

| 26.28% | O: 0.05% H: 1.33% C: 0.38%
ALNY | $143.8 -1.55% -1.58% 390K

Health Technology

| -25.89% | O: 5.53% H: 5.23% C: -2.49%
disease alzheimer’s positive results

Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy
Published: 2021-01-07 (Crawled : 15:00) - biospace.com/
ALNY | $143.8 -1.55% -1.58% 390K

Health Technology

| 15.17% | O: 5.35% H: 4.77% C: 4.33%
positive results phase 3 topline

Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
Published: 2023-11-02 (Crawled : 00:00) - biospace.com/
JNJ | News | $148.53 -0.69% -0.14% 9.6M

Health Technology

| 0.46% | O: -0.89% H: 0.0% C: 0.0%
XNCR | $19.05 3.7% 3.57% 760K

Health Technology

| 5.15% | O: 1.32% H: 0.45% C: -1.19%
VIR | $8.04 -1.11% -1.12% 770K

Health Technology

| 4.36% | O: 1.03% H: 4.07% C: 4.07%
ALNY | $143.8 -1.55% -1.58% 390K

Health Technology

| -6.96% | O: 3.4% H: 0.57% C: -0.5%
update financial results

New Long-Term Results for GIVLAARI® (givosiran) Presented at UEG Week Virtual 2021
Published: 2021-10-04 (Crawled : 13:00) - alnylam.com
ALNY | $143.8 -1.55% -1.58% 390K

Health Technology

| -22.59% | O: 3.34% H: 1.56% C: 0.01%
results

Alnylam Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Period Activity
Published: 2023-11-02 (Crawled : 13:00) - biospace.com/
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| 3.11% | O: 3.0% H: 0.0% C: 0.0%
ALNY | $143.8 -1.55% -1.58% 390K

Health Technology

| -6.96% | O: 3.4% H: 0.57% C: -0.5%
pharmaceuticals financial results

Alnylam Issues Inaugural Corporate Responsibility Summary
Published: 2021-03-11 (Crawled : 14:19) - biospace.com/
ALNY | $143.8 -1.55% -1.58% 390K

Health Technology

| 8.46% | O: 2.62% H: 3.97% C: 3.45%
response

Regeneron Reports Third Quarter 2023 Financial and Operating Results
Published: 2023-11-02 (Crawled : 11:00) - globenewswire.com
SNY | News | $46.66 -2.16% -2.21% 1.7M

Health Technology

| 3.11% | O: 3.0% H: 0.0% C: 0.0%
REGN | News | $906.55 -0.09% -0.08% 370K

Health Technology

| 14.67% | O: 0.08% H: 4.96% C: 3.4%
NTLA | $21.16 -1.72% -1.75% 860K

Health Technology

| -15.57% | O: 2.35% H: 1.63% C: 1.46%
ALNY | $143.8 -1.55% -1.58% 390K

Health Technology

| -6.96% | O: 3.4% H: 0.57% C: -0.5%
financial results

RNAi Technology Global Market to Reach $3.5 Billion by 2028 at a CAGR of 10.1%
Published: 2022-12-12 (Crawled : 22:00) - prnewswire.com
TMO | News | $577.39 0.49% 0.0% 2M

Health Technology

| 0.06% | O: 2.32% H: 0.0% C: 0.0%
SLN | $22.33 -0.8% -0.81% 110K

Health Technology

| 47.12% | O: 1.63% H: 13.76% C: -6.11%
PHIO | News | $0.672 -4.0% -4.17% 91K

Health Technology

| -85.77% | O: -4.12% H: 6.87% C: 1.78%
ALNY | $143.8 -1.55% -1.58% 390K

Health Technology

| -38.07% | O: 1.46% H: 0.99% C: -0.97%
global technology market

Global Gene Therapy Market Report 2021: Adeno-associated Virus Vectors - A Leading Platform for Gene Therapy
Published: 2021-07-13 (Crawled : 11:00) - prnewswire.com
QURE | $4.57 -3.79% -3.94% 640K

Health Technology

| -83.16% | O: -0.64% H: 1.28% C: -1.0%
SRPT | $124.27 6.11% 5.75% 1.3M

Health Technology

| 65.68% | O: -0.88% H: 1.98% C: -1.13%
SGMO | News | $0.4911 -5.72% -6.07% 1.2M

Health Technology

| -94.9% | O: -0.49% H: 1.63% C: 0.0%
RGNX | $16.05 0.94% 0.93% 350K

Health Technology

| -57.13% | O: -0.51% H: 0.95% C: -1.06%
ORTX | $16.7 0.0% 370K

Health Technology

| 337.63% | O: 0.05% H: 0.22% C: -4.26%
NTLA | $21.16 -1.72% -1.75% 860K

Health Technology

| -85.46% | O: -0.48% H: 1.36% C: -2.65%
GILD | $67.07 0.06% 0.06% 8.3M

Health Technology

| -1.53% | O: -0.35% H: 1.01% C: 0.27%
EDIT | News | $5.355 -1.92% -1.96% 1.6M

Health Technology

| -88.15% | O: -0.15% H: 1.2% C: -4.78%
CRSP | News 4 | $55.66 -1.33% -1.35% 910K

Health Technology

| -59.92% | O: -0.47% H: 0.76% C: -3.24%
BLUE | $0.9274 -4.45% -4.66% 8.1M

Health Technology

| -96.74% | O: -0.7% H: 0.95% C: -2.43%
AGTC | News | $0.3936 1.23% 0.0%

Health Technology

| -89.75% | O: -0.52% H: 0.0% C: -2.09%
ALNY | $143.8 -1.55% -1.58% 390K

Health Technology

| -17.49% | O: -0.56% H: 1.51% C: -0.23%
ADAP | $1.085 -4.83% -5.07% 780K

Health Technology

| -71.14% | O: -0.25% H: 0.25% C: -1.78%
ABEO | News | $3.165 -7.19% -7.74% 2.2M

Health Technology

| 140.14% | O: 2.11% H: 0.0% C: -4.83%
gene therapy therapy gene therapies

Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
ALNY | $143.8 -1.55% -1.58% 390K

Health Technology

| 11.85% | O: 2.06% H: 0.0% C: 0.0%
cardiac results phase 3

Senda Biosciences Appoints Stuart Milstein, Ph.D., as SVP and Head of Platform Biology
Published: 2022-01-26 (Crawled : 15:30) - biospace.com/
OMGA | $2.335 -0.21% -0.21% 200K

| -75.78% | O: 1.86% H: 22.56% C: 11.79%
SANA | $8.58 6.06% 5.71% 1.2M

| -4.94% | O: 2.47% H: 2.98% C: -7.11%
SGTX | $22.47 -2.56% 0.0% 0

Health Technology

| 1129.95% | O: 3.74% H: 7.73% C: -6.7%
MCRB | $0.7295 -4.01% -4.18% 5.8M

Health Technology

| -90.18% | O: 2.33% H: 4.55% C: -2.78%
RUBY | $0.057 -99.3% 760K

Health Technology

| -99.24% | O: 1.93% H: 1.76% C: -5.95%
MRNA | News S | $108.82 0.86% 0.85% 3.4M

Health Technology

| -29.27% | O: 3.57% H: 4.97% C: -1.92%
FHTX | $5.21 0.97% 0.96% 110K

Health Technology

| -66.03% | O: 2.83% H: 4.29% C: -4.8%
EVLO | $0.3165 -87.39% 710K

Health Technology

| -93.93% | O: 0.58% H: 3.82% C: -6.87%
DNLI | $15.55 -3.48% -3.6% 940K

Health Technology

| -52.24% | O: 2.67% H: 4.36% C: -3.98%
CDAK | $0.057 -55.99% -131.25% 0

Health Technology

| -99.15% | O: 3.13% H: 0.55% C: -8.97%
AXLA | $4.58 -56.33% 42K

Health Technology

| 180.98% | O: 2.45% H: 3.9% C: -0.48%
ALNY | $143.8 -1.55% -1.58% 390K

Health Technology

| 11.55% | O: 2.02% H: 2.38% C: -2.59%
bioscience platform

Alnylam Pharmaceuticals Files Patent Infringement Suits against Pfizer and Moderna
Published: 2022-03-17 (Crawled : 12:00) - biospace.com/
PFE | News 4 | $26.27 -0.19% -0.15% 23M

Health Technology